StockNews.AI
ANIK
StockNews.AI
174 days

Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025

1. ANIK to announce Q4 and year-end financial results on March 12, 2025. 2. Investor call scheduled to discuss financial results and business highlights. 3. Focus on osteoarthritis pain management and regenerative orthopedic solutions. 4. Products are delivered in key care sites, enhancing market reach.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings announcements often lead to increased investor interest. Positive results may drive share prices up, as seen historically in similar firms.

How important is it?

The upcoming earnings call provides critical insight into ANIK's performance, affecting investor decisions significantly.

Why Short Term?

The financial results on March 12 could provide immediate impacts on the stock. Historical earnings releases typically result in swift price movements based on reported numbers.

Related Companies

AMGNREGNSNY
February 26, 2025 08:00 ET  | Source: Anika Therapeutics Inc. BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89368. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion. About AnikaAnika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com. ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc. For Investor Inquiries:Anika Therapeutics, Inc.Matt Hall, 781-457-9554Director, Corporate Development and Investor Relationsinvestorrelations@anika.com

Related News